IGC Pharma
29 hedge funds and large institutions have $3.97M invested in IGC Pharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 3 closing their positions.
290% more call options, than puts
Call options by funds: $409K | Put options by funds: $105K
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3.99% less ownership
Funds ownership: 12.19% → 8.2% (-4%)
35% less capital invested
Capital invested by funds: $6.07M → $3.97M (-$2.11M)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$40.3K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$26K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14K |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.67K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$940 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$1.44M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$276K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$163K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$88K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$45.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wolverine Trading
Chicago,
Illinois
| – | -$12.1K | -12,462 | Closed |
|
|
FIA
27
FNY Investment Advisers
New York
| – | -$11.7K | -12,000 | Closed |
|
|
CG
28
Cutler Group
San Francisco,
California
| – | -$1.56K | -1,604 | -67% |
|
29
Wells Fargo
San Francisco,
California
| – | +$1 | +1 | +0.4% |
|
IGC Hedge Fund Activity: Q1 2022 in Review
29 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2022, worth a combined $3.97M — down 35% from $6.07M a quarter earlier.
Fund positioning in IGC was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 12 trimmed.
The largest buyer was Vident Investment Advisory, adding an estimated $40.3K. The largest seller was IQ EQ Fund Management, cutting an estimated $1.44M.
- 29 institutional investors held IGC Pharma (IGC) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $3.97M of IGC Pharma stock for Q1 2022, down 35% quarter-over-quarter.
- 3 funds opened new IGC Pharma positions in Q1 2022 and 3 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q1 2022 was Vident Investment Advisory, an estimated $40.3K added.
- The largest IGC Pharma seller in Q1 2022 was IQ EQ Fund Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q1 2022.